Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Vetisulid Injection

This page contains information on Vetisulid Injection for veterinary use.
The information provided typically includes the following:
  • Vetisulid Injection Indications
  • Warnings and cautions for Vetisulid Injection
  • Direction and dosage information for Vetisulid Injection

Vetisulid Injection

This treatment applies to the following species:
Manufacturer: Boehringer Ingelheim

Sodium Sulfachlorpyridazine Injection


NADA 33-318 Approved by FDA


Vetisulid Injection (Sodium Sulfachlorpyridazine Injection) is a sterile, aqueous solution for intravenous use. Each mL provides 215 mg (21.5%) sodium sulfachlorpyridazine (equivalent to 200 mg sulfachlorpyridazine), 16 mg benzyl alcohol and sodium hydroxide to adjust the pH.


Sulfachlorpyridazine is a broad spectrum antibacterial compound which is effective in the treatment of infections caused by gram-positive and gram-negative organisms that are commonly susceptible to sulfonamide therapy and which has been proven by laboratory and field experiments to be highly effective against diseases caused by Escherichia coli.

Sulfachlorpyridazine has a rapid onset of action in several species of animals following both oral and parenteral administration. In comparison with other sulfonamides, the administration of comparatively effective oral doses of sulfachlorpyridazine to dogs produces blood concentrations that reach maximum levels in 1 to 3 hours. The blood level declines to 1 to 2 mg-percent after 12 hours and the drug is completely excreted in the urine within 48 hours. In experimental studies in which cattle are given the recommended dosage of sulfachlorpyridazine intravenously, the blood level rises to above 12 mg-percent within 1 hour and 6 hours later it falls to 3 to 4 mg-percent; after 18 hours no sulfonamide can be detected. In swine given the recommended dosage of sulfachlorpyridazine either intramuscularly or orally, the blood level reaches 5.5 mg-percent after 1.5 hours. The blood level declines to 1 to 2 mg-percent within 6 hours; after 12 hours practically no sulfonamide can be detected. Laboratory studies with other species of animals have demonstrated similar responses in blood and urine following oral or parenteral administration of sulfachlorpyridazine.

Sulfachlorpyridazine is readily soluble at normal urinary pH making it unlikely that crystallization of the free and acetylated forms will occur.

Studies with laboratory animals indicate that sulfachlorpyridazine attains a high concentration in the bile; the concentrations in the liver and kidneys approximately parallel that of the blood, thus demonstrating excellent penetration of tissues.

Veterinary laboratories have confirmed the exceptional activity of sulfachlorpyridazine against E. coli by both in vitro and in vivo tests. In one study, 64 out of 70 E. coli strains that were isolated from clinical cases of colibacillosis in calves were sensitive to sulfachlorpyridazine. Another sensitivity study involving calves revealed 225 isolates of E. coli that were sensitive to sulfachlorpyridazine out of a total of 226 isolates examined. Pretreatment and post-treatment identifications of various serotypes of E. coli were made in this study. In all serotypes, except one, the number of isolates cultured from the feces of treated calves was reduced following treatment with sulfachlorpyridazine. Results from a study in swine revealed that 110 out of 118 strains of E. coli isolated from swine enteritis were sensitive to sulfachlorpyridazine. Clinical studies confirm its efficacy in treating E. coli infections.

Vetisulid Injection Indications

Vetisulid Injection (Sodium Sulfachlorpyridazine Injection), is especially indicated for the treatment of diarrhea caused or complicated by E. coli (colibacillosis) in calves under 1 month of age.


Treated, ruminating calves must not be slaughtered for food during treatment and for 5 days after the last intravenous treatment.


A Withdrawal Period Has Not Been Established For These Products In Pre-ruminating Calves. Do Not Use In Calves To Be Processed For Veal.

Vetisulid Injection Caution

The diagnosis should be reconfirmed if symptoms persist for 2 to 3 days.

To insure adequate urine flow and to prevent crystalluria, water should be readily available to animals receiving sulfachlorpyridazine therapy.

Vetisulid Injection Dosage And Administration


The recommended daily dose is 30 to 45 mg of sulfachlorpyridazine per lb of body weight administered in 2 divided doses for 1 to 5 days, as follows:

Vetisulid Injection (sodium Sulfachlorpyridazine Injection) - Administer Intravenously 1 Ml Per 10 Lb Of Body Weight Morning And Night.

it Is Suggested That Therapy Be Initiated By Administering Vetisulid Injection Intravenously And Continuing Therapy With The Oral Administration Of Either Vetisulid Boluses Or Vetisulid Powder.

how Supplied

Vetisulid Injection (Sodium Sulfachlorpyridazine Injection) is supplied in 250 mL multiple dose vials.


Vetisulid Injection: Protect from light. Store at room temperature; avoid freezing.

Manufactured for

Fort Dodge Animal Health, Fort Dodge, Iowa 50501 Usa



Iss. 11-98


Nac No.


Telephone:   800-325-9167
Fax:   816-236-2717
Every effort has been made to ensure the accuracy of the Vetisulid Injection information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2018 North American Compendiums. Updated: 2018-04-26